Medtronic (MDT) Stock Forecast and Price Target 2026 $MDT

Consensus Rating

Consensus Price Target

Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts’ ratings for Medtronic and its competitors.

Sign Up

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Medtronic

Bull Case

Here are some ways that investors could benefit from investing in Medtronic plc:

• Medtronic plc recently reported strong financial results for the quarter ended September 1, 2026, beating analyst expectations with earnings per share of $1.45 compared to a consensus estimate of $1.39, while revenue of $9.76 billion exceeded the expected $9.55 billion, demonstrating robust fundamental performance and a 13.7% year-over-year revenue increase.
• The stock is currently trading at $94.12, which is below the average analyst price target of $98.83 as of August 21, 2026, suggesting potential upside for investors as the consensus rating remains a Moderate Buy with 19 analysts issuing Buy ratings versus nine Hold ratings.
• Medtronic plc offers a dividend yield of 3.09%, with a recent quarterly dividend of $0.72 per share declared for payment on October 16, 2026, providing a steady income stream for investors despite a payout ratio of 70.94%.
• New real-world evidence from the PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system, which could improve adoption prospects and strengthen the pain-management franchise, adding a positive catalyst for the Neuroscience Portfolio segment.
• Institutional investors are showing renewed interest, with Oakmont Investment Advisors Inc. acquiring a new stake of 26,858 shares valued at approximately $2.10 million in the second quarter, and NEOS Investment Management LLC boosting its holdings by 9.7%, indicating growing confidence among professional investors.

Medtronic

Bear Case

Investors should be bearish about investing in Medtronic plc for these reasons:

• A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains, which raises the risk of profit-taking or volatility despite the positive fundamental backdrop.
• Wall Street Zen downgraded Medtronic from a Buy rating to a Hold rating on September 5, 2026, reflecting a more cautious outlook from at least one analyst firm, which could signal a shift in sentiment among some market participants.
• Short interest in Medtronic shares increased to 14,350,429 shares as of August 14, 2026, representing a 1.12% short percentage of float, indicating that some investors are betting against the stock’s future performance, although the days to cover is relatively low at 2.25.
• Insider selling activity has been notable, with EVP Harry Skip Kiil selling 4,189 shares at an average price of $80.44 on June 8, 2026, and previously selling 52,524 shares at $97.71 on February 19, 2026, which may raise concerns about executive confidence in the stock’s near-term valuation.
• The company’s debt-to-equity ratio stands at 0.52, and while the current ratio is healthy at 2.13, the high payout ratio of 70.94% for dividends could limit flexibility for future capital expenditures or share buybacks if revenue growth slows.